Company Overview
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -2.66% |
| 6 Months: | +7.02% |
| 3 Months: | +2.23% |
| 1 Month: | +14.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 26.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OSTX OS Therapies Incorporated PHARMA | 1.83 | -1.68 | $85.65M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 5.00M | 4.84M | 6.88M | 11.99M | 10.17M |
| Operating Income | -1.05M | -1.52M | -622.21K | -630.23K | -779.80K | -2.44M | - | -5.00M | -4.84M | -6.88M | -11.99M | -10.17M |
| EBITDA | - | - | - | - | - | - | - | -3.88M | -4.42M | -6.75M | -13.34M | -10.20M |
| Interest Expense | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 75.34K |
| Pretax Income | - | - | - | - | - | - | - | -3.88M | -4.54M | -6.88M | -13.46M | -10.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.85M | -2.51M | -1.97M | -1.46M | -1.56M | -2.88M | - | -3.88M | -4.54M | -6.88M | -13.46M | -10.40M |
| Diluted EPS | - | -0.47 | -0.38 | -0.25 | -0.26 | -0.18 | - | -0.18 | -0.19 | -0.21 | - | -0.27 |
| R&D Expense | 753.78K | 992.90K | 454.50K | 361.81K | 396.57K | 1.21M | - | 1.31M | 2.50M | 3.76M | - | 7.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 4.45M | 4.34M | 6.81M | 28.71M |
| Operating Income | - | -4.45M | -4.34M | -6.81M | -28.71M |
| EBITDA | - | -4.45M | -4.34M | -6.83M | -28.39M |
| Interest Expense | - | 1.81M | 3.45M | 2.05M | 0 |
| Pretax Income | - | -6.25M | -7.79M | -8.88M | -28.75M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -6.25M | -7.79M | -8.88M | -28.75M |
| Diluted EPS | - | -0.32 | -0.38 | -1.28 | -0.98 |
| R&D Expense | - | - | 3.22M | 2.84M | 16.36M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 509.11K | 798.08K | 5.54M | 6.84M |
| Current Assets | - | 496.83K | 790.03K | 5.53M | 332.91K |
| Cash & Equivalents | - | 171.48K | 38.98K | 5.53M | 269.83K |
| Inventory | - | - | - | - | - |
| Receivables | 231.07K | 1.15K | 0 | - | - |
| Total Liabilities | - | 18.07M | 24.81M | 8.81M | 12.94M |
| Current Liabilities | - | 6.15M | 24.71M | 4.63M | 11.76M |
| Long Term Debt | 7.07M | 10.35M | - | - | - |
| Total Debt | 7.07M | 10.35M | 14.61M | - | - |
| Total Equity | - | -17.56M | -24.02M | -3.27M | -6.10M |
| Shares Outstanding | - | 20.60M | 20.60M | 20.87M | 37.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -3.79M | -3.01M | -7.28M | -14.24M |
| Investing Cash Flow | - | 230.88K | 1.15K | 0 | -466.42K |
| Financing Cash Flow | - | 3.65M | 2.87M | 12.78M | 9.44M |
| Capital Expenditure | -11.93K | - | - | - | -466.42K |
| Free Cash Flow | - | -3.79M | -3.01M | -7.28M | -14.70M |
| Net Change in Cash | - | 90.69K | -132.50K | 5.49M | -5.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 35.6% | 32.4% | 271.9% | 471.7% |
| ROCE % | - | 78.9% | 18.2% | -747.6% | 582.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 16.93% | 777.65K | $1.38M |
| 2 | CM Management, LLC | 8.71% | 400.00K | $708.00K |
| 3 | Geode Capital Management, LLC | 6.57% | 301.79K | $534.17K |
| 4 | Howard Financial Services, Ltd. | 5.40% | 248.00K | $438.96K |
| 5 | Blackrock Inc. | 5.28% | 242.48K | $429.19K |
| 6 | Vanguard Fiduciary Trust Co | 3.79% | 174.13K | $308.21K |
| 7 | State Street Corporation | 2.61% | 120.10K | $212.58K |
| 8 | Marshall Wace LLP | 2.19% | 100.64K | $178.13K |
| 9 | HighTower Advisors, LLC | 1.86% | 85.55K | $151.42K |
| 10 | Northern Trust Corporation | 1.54% | 70.82K | $125.35K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSTX
An interim cancer-trial analysis found 71.2% three-year survival versus 45.8% in a historical group. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSEtKTy03TXVVUUtTR21nc05VU0lZM1FKRGxkRXQ1V2hFcS1VeDl2SmYyTDZrQS1MSFdncGxDV1FXTVUzUGlPOE1tbHNqcTNTSlA4d05URGhHaS0taXNjTHFVN0JHbHFkV2NaMnIzdFkta2QtSmtCanh0TmN4Tlo0SnNsZHJZNnJTbHV5UU…
OS THERAPIES INC (OSTX) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE1PTWdXOG85TkpKVHpoVDMtSU1nZlNFc0xLOU5rT2JqV1U0QUxYTm0tUG12SmxJOU1CSGtQUVdhYUlPX3R6OUdJaGJIZDZBbU9kQmgxT0JzSks3bnMxUC1RVkJPMjM?oc=5" target="_blank">OS THERAPIES INC (OSTX) Stock Ch…
OSTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5OcldqbFhfNjIwSWRtZHE5VjRkUXNfbDh2Qi1EZ3BpZHZqZHBfaTgxc0ZILXJMRW85elc5YkYtc2dxcS0yOEE?oc=5" target="_blank">OSTX</a> <font color="#6f6f6f">Finviz</font>…
OSTX Analyst Rating Maintained at 'Buy' with $20 Price Target | OSTX Stock News - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNeEZCV3FKR1k3TTloZVMxMzRBM25rSm5IcDI4UG80S1FUVmZYbFY5TXk3WDFhbWc2dXlRMlFzR2NiUGllb2drTEdKdTVVTDMtMlpfcEhTX3pLM3V5Q3RyU0lyTUw5aURwazNIaU5USjMyQldLN1ZDc3Y0ZktQU1BHLVlrT01iRWJRbDBCLV…
Lake Street Maintains OS Therapies(OSTX.US) With Buy Rating, Maintains Target Price $13 - Moomoo
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQWU9pd1VHVGZoQVNlLUQyNC0wX1cyYTRxbDhxX3hGVjMzNTRkV3c4eXZSbEJ5OGFBd3hDUTFLNGlLSUpuNVROd0xtU2RUc09QTXVyYWs2RUJrV2NIbHhjODU3eFY4ekZNMVNnaDlaTE5zR1pBRC11OGZSLThGUjdjTHVSUmRucU05UC1Qbk…
OS Therapies Expects 3-Year Survival Data in September - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNTzBqV3plbEJEem9oU2txZ1NIZDRpd21TWXJOM05nbU5EMlFZUGluYkgtclB0ZlNFU056QVAzNWNaSjg2SUJIdG5MaGlJNVN2WEpmNEtVZGNmam5vTFMwLXJFaE9EMWdKTEl1Y25jbTEwZEdaQkplN3hCMGtBYmF1TVEydE54OWZJOVhBUT…
OSTX — Frequently Asked Questions
What is the current share price of OS Therapies Incorporated (OSTX)?
As of 2026-09-19 21:16 PDT, OS Therapies Incorporated (OSTX) trades at $1.83 on NYSE American. Its 52-week range is $1.16 to $2.50.
What is the market capitalisation of OSTX?
OS Therapies Incorporated (OSTX) has a market capitalisation of $85.65M on NYSE American.
What is the P/E ratio of OSTX?
OSTX trades at a trailing price-to-earnings (P/E) ratio of -1.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -6.73.
Is OSTX a good stock to buy?
This page provides a data-driven analysis of OS Therapies Incorporated (OSTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.